We spoke with management who noted that the company is encouraged by the initial assessment of the 0.5 mg dose of off schedule (21/7), which could be a potl. recommended Phase II dose (RP2D) and are now evaluating a 0.75mg 21/7 schedule with a final RP2D determination and data presentation anticipated in 2H24. Recall, MRT-2359 is being developed as a potential first-in-class therapy for patients with MYC-driven cancers, including NSCLC (also see here). MRT-6160 is a potent, selective, and orally bioavailable degrader of VAV1, expressed in T and B cells and a potential new target for autoimmune diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), multiple sclerosis (MS), and dermatological disorders. GLUE is on track to initiate a Ph. I SAD/ MAD study this summer, with initial trial results guided to Q1 2025.